Search
Raxibacumab
go.drugbank.com/drugs/DB08902ApprovedInvestigationalRaxibacumab is produced by recombinant DNA technology in a murine cell expression system. FDA approved on December 14, 2012. … Raxibacumab is a human IgG1λ monoclonal antibody that binds the protective antigen (PA) component of B. anthracis toxin. Raxibacumab has a molecular weight of approximately 146 kilodaltons.
Synonyms: PA mAbDavesomeran
go.drugbank.com/drugs/DB17091ApprovedInvestigationalModerna Bivalent vaccine elicit a higher seroresponse both against the original SARS-CoV-2 strain and the BA.4/5 strain compared to that of the Moderna COVID-19 Vaccine. … [L43882] A phase 2 and 3 open-label study in participants 18 years or older who had previously received a two-dose primary series and one booster dose of Moderna COVID-19 Vaccine demonstrated that the
Mixtures: Spikevax Bivalent (original / Omicron Ba.4/5)Albuterol
go.drugbank.com/drugs/DB01001ApprovedInvestigationalVet approvedSalbutamol is formulated as a racemic mixture of the R- and S-isomers. … Salbutamol (Albuterol [USAN]) is a short-acting, selective beta2-adrenergic receptor agonist used in the treatment of asthma and COPD.
Products: SALBUTAMOL JARABE DE 2 MG/5ML, SALBUTAMOL 1A PHARMA 0.1MGAprocitentan
go.drugbank.com/drugs/DB15059ApprovedInvestigational[A263386,L50261] Aprocitentan was approved by the FDA in March 2024 for the treatment of hypertension in patients inadequately controlled with standard therapy. … blocker, and a diuretic at maximally tolerated doses.
Chlorthalidone
go.drugbank.com/drugs/DB00310ApprovedInvestigationalThese pathways may play a role in chlorthalidone's cardiovascular risk reduction effects.[A176330] … Chlorthalidone has been shown to have a number of pleiotropic effects that differentiate it from other diuretics such as [DB00999].
Mixtures: Aa-atenidone, Aa-atenidoneCidofovir
go.drugbank.com/drugs/DB00369ApprovedInvestigationalIt suppresses CMV replication through selective inhibition of viral DNA synthesis. … [FDA label] It was manufactured by _Gilead_ and initially approved by the FDA in 1996, but has since been discontinued.[L6223]
Categories: Cytomegalovirus Nucleoside Analog DNA Polymerase InhibitorBifenthrin
go.drugbank.com/drugs/DB15056ExperimentalBifenthrin is under investigation in clinical trial NCT01560247 (Percutaneous Recanalization in Ischemic Stroke Management in Europe Observational Registry).
Omega-3-carboxylic acids
go.drugbank.com/drugs/DB09568ApprovedWithdrawnThe omega-3 carboxylic acid (OM3-CA) is a new formulation of omega-3 fatty acids that present an enhanced bioavailability in the treatment of dyslipidemia. … The increased bioavailability is explained because OM3-CA is found in a form of polyunsaturated free fatty acids as opposed to other products whose form is as ethyl esters.
Amitriptyline
go.drugbank.com/drugs/DB00321ApprovedInvestigationalAmitriptyline is a tricyclic antidepressant that has been used to treat depression for decades. ELAVIL, a previously approved branded product of amitriptyline, was first approved by the FDA in 1961.
Mixtures: Limbitrol DS, Etrafon D TabCategories: Monoamine Oxidase A Inhibitors for interaction with Monoamine Oxidase A substrates, P-glycoprotein substrates with a Narrow Therapeutic IndexSerdexmethylphenidate
go.drugbank.com/drugs/DB16629Approved[L32298, L32323] Serdexmethylphenidate was granted FDA approval on March 2, 2021, and is currently marketed as a combination capsule with [dexmethylphenidate] under the trademark AZSTARYS™ by KemPharm … [A230698, A230708] Serdexmethylphenidate is a prodrug of the CNS stimulant [dexmethylphenidate], a common first-line treatment for ADHD, that is combined with [dexmethylphenidate] to provide extended plasma